| Sažetak | Cilj istraživanja: Prikazati i usporediti razliku u koncentraciji CD163 proteina između
oboljelih od multiple skleroze i zdrave populacije. Utvrditi povezanost između koncentracije
CD163 i kliničke procjene stanja onesposobljenosti pacijenata s RRMS-om te usporediti razliku
u koncentraciji CD163 proteina s obzirom na spol oboljelih od MS-a.
Ispitanici i postupci: Uključeno je dvadeset i tri bolesnika s RRMS-om koji su primali
teriflunomid, prosječne dobi od 41,65 ± 8,89 i deset zdravih kontrolnih osoba s prosječnom
dobi od 37 ± 13,9. Prosječno trajanje bolesti bilo je 9,39 ± 5,73 godine, a medijan EDSS
rezultata bio je 2,5 (3,0). Od 23 pacijenta s MS-om, 57,8% je primilo kortikosteroidnu terapiju
tri ili više od tri puta tijekom cijelog liječenja. Nitko od pacijenata nije doživio recidiv 3 mjeseca
prije sudjelovanja u ovoj studiji. Najprije je obavljena radiološka MRI procjena mozga i leđne
moždine. Nakon tog koraka, serum je prikupljen za jedan ili dva dana, a potom je izvršen
neurološki pregled. Kvantitativno mjerenje CD163 u serumu izvršilo se korištenjem Human
CD163 ELISA Kit (M130) (ab155428). Uspoređene su koncentracije CD163 u serumu između
bolesnika i zdravih kontrola te između spolova oboljelih od RRMS-a te se pokušala utvrditi
povezanost koncentracije CD163 i EDSS-a. Statistička značajnost postavljena je na P<0,05.
Rezultati: Od ukupno 23 ispitanika oboljela od MS-a, 14 je ženskog (60,87%), a 9 muškog
spola (39,13%), stoga je omjer žene:muškarci 1,56:1. 15 ih je imalo teži klinički oblik (65,22%),
a 8 blaži klinički oblik (34,78%). Nije bilo statistički značajnih razlika u koncentraciji CD163
proteina u serumu između sudionika s različitom težinom kliničkih oblika RRMS-a, kao ni
razlika između sudionika s RRMS-om i zdrave kontrolne skupine (P>0,05). Rezultati sCD163
u bolesnika s težom kliničkom slikom iznosili su 834,57±335,29 ng/ml, u bolesnika s lakšom
kliničkim oblikom 720,31±156,98 ng/ml, a u zdravoj kontroli 591,75±225,10 ng/ml. Nije
utvrđena statistički značajna korelacija između serumske koncentracije CD163 i EDSS-a.
Medijan EDSS bolesnika s težim oblikom iznosio je 3,50 (2-3,50), a u onih s lakšim oblikom
1,00 (0,0-2,0). Muškarci imaju značajno višu koncentraciju CD163 u odnosu na žene (P<0,05).
Prosječna koncentracija CD163 za muškarce iznosili su 947±227 ng/ml, a za žene 697±285
ng/ml.
Zaključak: Koncentracija CD163 proteina u serumu se između bolesnika s različitom težinom
kliničkih oblika RRMS-a međusobno, ali i u odnosu na zdravu populaciju ne razlikuje značajno.
Ne postoji povezanost između razine CD163 i kliničke procjene stanja onesposobljenosti
pacijenata s RRMS-om. Muškarci imaju višu koncentraciju CD163 u odnosu na žene. |
| Sažetak (engleski) | Objectives: To show and compare the difference in CD163 protein concentration between
patients with multiple sclerosis and the healthy population. To determine the relationship
between the concentration of CD163 and the clinical assessment of the condition of patients
with RRMS and to compare the difference in the concentration of the CD163 protein with
regard to the gender of patients with MS.
Subjects and methods: Twenty-three patients with RRMS receiving teriflunomide, mean age
of 41,65 ± 8,89, and ten healthy controls with a mean age of 37 ± 13,9 were included. The
average duration of the disease was 9,39 ± 5,73 years, and the median EDSS score was 2,5
(3,0). Of the 23 patients with MS, 57,8% received corticosteroid therapy three or more times
during the entire treatment. None of the patients experienced a relapse 3 months prior to
participation in this study. First, a radiological MRI assessment of the brain and spinal cord was
performed. After this step, the serum was collected for one or two days, and then a neurological
examination was performed. Quantitative measurement of CD163 in serum was performed
using the Human CD163 ELISA Kit (M130) (ab155428). Serum CD163 concentrations were
compared between patients and healthy controls and between genders of RRMS patients, and
an attempt was made to determine the relationship between CD163 concentration and EDSS.
Statistical significance was set at P<0,05.
Results: Out of a total of 23 subjects, 14 were female (60,87%), and 9 were male (39,13%), so
the female:male ratio was 1,56:1. 15 of them had a severe clinical form (65,22%), and 8 had a
mild clinical form (34,78%). There were no statistically significant differences in serum CD163
protein concentration between participants with different severity of clinical forms of RRMS,
nor differences between participants with RRMS and healthy controls (P>0,05). The results of
sCD163 in patients with a severe clinical picture were 834,57±335,29 ng/ml, in patients with a
mild clinical form 720,31±156,98 ng/ml, and in healthy controls 591,75±225,10 ng/ml. No
statistically significant correlation was found between serum CD163 concentration and EDSS.
The median EDSS of patients with a severe form was 3,50 (2-3,50), and for those with a milder
form it was 1,00 (0,0-2,0). Men have a significantly higher concentration of CD163 compared
to women (P<0,05). The average concentration of CD163 for men was 947±227 ng/ml, and for
women 697±285 ng/ml.
Conclusion: The concentration of CD163 protein in the serum between patients with different
severity of clinical forms of RRMS does not differ significantly from each other, but also in
relation to the healthy population. There is no association between CD163 levels and clinical assessment of disability status in patients with RRMS. Men have a higher concentration of
CD163 than women. |
